300 related articles for article (PubMed ID: 18978334)
1. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
James PA; Harris M; Lindeman GJ; Mitchell G
J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
[No Abstract] [Full Text] [Related]
2. Genomic rearrangements in the BRCA1 and BRCA2 genes.
Mazoyer S
Hum Mutat; 2005 May; 25(5):415-22. PubMed ID: 15832305
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
4. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
Hopper JL; Dowty JG; Apicella C; Southey MC; Giles GG; Winship I
J Med Genet; 2008 Jul; 45(7):409-10. PubMed ID: 18456714
[No Abstract] [Full Text] [Related]
5. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
6. Mutations of BRCA genes in hereditary breast and ovarian cancer.
Radice P
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):9-12. PubMed ID: 12585647
[TBL] [Abstract][Full Text] [Related]
7. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
8. Optimal selection of individuals for BRCA mutation testing.
Evans DG; Lalloo F; Eccles D
J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
[No Abstract] [Full Text] [Related]
9. BRCA1 and BRCA2 cancer risks.
Antoniou AC; Pharoah PD; Easton DF; Evans DG
J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
[No Abstract] [Full Text] [Related]
10. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
11. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
[No Abstract] [Full Text] [Related]
12. Breast cancer risks for BRCA1/2 carriers.
Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
[No Abstract] [Full Text] [Related]
13. Cancer. A risky business--assessing breast cancer risk.
Levy-Lahad E; Plon SE
Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
[No Abstract] [Full Text] [Related]
14. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
15. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.
Fackenthal JD; Olopade OI
Nat Rev Cancer; 2007 Dec; 7(12):937-48. PubMed ID: 18034184
[TBL] [Abstract][Full Text] [Related]
16. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
[No Abstract] [Full Text] [Related]
17. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
18. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
Bellcross CA; Kolor K; Goddard KA; Coates RJ; Reyes M; Khoury MJ
Am J Prev Med; 2011 Jan; 40(1):61-6. PubMed ID: 21146769
[TBL] [Abstract][Full Text] [Related]
19. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma.
Piek JM; Dorsman JC; Zweemer RP; Verheijen RH; van Diest PJ; Colgan TJ
Int J Gynecol Pathol; 2003 Jul; 22(3):315-6; author reply 315-6. PubMed ID: 12819403
[No Abstract] [Full Text] [Related]
20. DNA testing. Genetic screen misses mutations in women at high risk of breast cancer.
Stokstad E
Science; 2006 Mar; 311(5769):1847. PubMed ID: 16574828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
